C2X.F - China Literature Limited
| Previous close | 3.7000 |
| Open | 3.6800 |
| Bid | 3.6600 x 0 |
| Ask | 3.8400 x 0 |
| Day's range | 3.6800 - 3.7000 |
| 52-week range | 2.4200 - 5.1500 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 3.803B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 45.75 |
| EPS (TTM) | 0.0800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR Newswire AsiaChina Literature Limited Announces Changes to its Management Team
China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual property ("IP") incubation platform in China, today announced that Mr. Cheng Wu has resigned from his positions as the Chief Executive Officer ("CEO") and the Executive Director of the Company due to the change of his personal life plan. Meanwhile, Mr. Hou Xiaonan, the President of the Company, has been appointed by the Board as the CEO, leading the Company's business op
PR Newswire AsiaChina Literature Announces 2022 Annual Results
China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual property ("IP") incubation platform in China, today announced the audited consolidated results for the year ended December 31, 2022.
- PR Newswire Asia
China Literature to Report Full Year 2022 Financial Results on March 16, 2023
China Literature Limited ("China Literature" or "the Company", 0772.HK), a leading online literature and intellectual property ("IP") incubation platform in China, will announce its financial results for the full year of 2022 on Thursday, March 16, 2023.
ZacksIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
ZacksWhy Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksHere's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ZacksThe Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
- Zacks
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.
ZacksChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Motley FoolWhy ChemoCentryx Stock Is On Fire Today
Shares of ChemoCentryx (NASDAQ: CCXI) skyrocketed by as much as 110% in premarket trading Thursday morning. The company's stock bolted higher following the news that biotech heavyweight Amgen (NASDAQ: AMGN) offered $3.7 billion in cash to acquire the rare-disease specialist. The deal represents a whopping 116% premium relative to where ChemoCentryx's shares closed on Wednesday.
ZacksWill Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
ZacksCatalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.